ANON
MCID: ANR007
MIFTS: 59

Anorexia Nervosa (ANON)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Anorexia Nervosa

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 57 12 73 72 54 44 15 17 70 32
Anorexia Nervosa, Susceptibility to, 1 57 13 39
Anorexia Nervosa 1 57 29
Anon 57 72
Anorexia Nervosa, Susceptibility to 57
an 57

Classifications:



External Ids:

Disease Ontology 12 DOID:8689
OMIM® 57 606788
ICD9CM 34 307.1
MeSH 44 D000856
NCIt 50 C34387
SNOMED-CT 67 192445002
ICD10 32 F50.0
MedGen 41 C1853221
UMLS 70 C0003125

Summaries for Anorexia Nervosa

OMIM® : 57 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788) (Updated 20-May-2021)

MalaCards based summary : Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, 1, is related to body dysmorphic disorder and eating disorder, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Fluoxetine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and pituitary, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

UniProtKB/Swiss-Prot : 72 Anorexia nervosa: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea.

Wikipedia : 73 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder, characterized by low... more...

Related Diseases for Anorexia Nervosa

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 745)
# Related Disease Score Top Affiliating Genes
1 body dysmorphic disorder 32.6 SLC6A4 IGF1 HTR2A
2 eating disorder 32.5 SLC6A4 PYY POMC NPY LEPR LEP
3 bulimia nervosa 32.2 SLC6A4 PYY NPY LEP HTR2A GHRL
4 amenorrhea 32.1 PRL POMC LEP IGF1 GHRL CRH
5 personality disorder 31.8 SLC6A4 PRL HTR2A CRH BDNF
6 hypoglycemia 31.7 PRL POMC IGF1 GH1 CRH
7 depression 31.7 SLC6A4 PRL HTR2A CRH BDNF
8 mental depression 31.6 SLC6A4 POMC HTR2A CRH BDNF
9 anxiety 31.5 SLC6A4 PRL POMC NPY HTR2A GHRL
10 mood disorder 31.4 SLC6A4 POMC NPY HTR2A CRH BDNF
11 neurotic disorder 31.4 SLC6A4 POMC HTR2A BDNF
12 obsessive-compulsive personality disorder 31.4 SLC6A4 HTR2A
13 insulin-like growth factor i 31.4 PRL LEP IGF1 GHRH GHR GH1
14 obsessive-compulsive disorder 31.3 SLC6A4 PRL POMC NPY LEP IGF1
15 borderline personality disorder 31.3 SLC6A4 PRL HTR2A CRH BDNF
16 constipation 31.3 SLC6A4 PYY NPY GHRL CCK BDNF
17 autism 31.2 SLC6A4 PRL POMC NPY LEP IGF1
18 celiac disease 1 31.2 PYY IGF1 GHRL CCK
19 alcohol use disorder 31.2 SLC6A4 HTR2A CRH BDNF
20 major depressive disorder 31.2 SLC6A4 PRL POMC NPY LEP HTR2A
21 substance abuse 31.2 SLC6A4 PRL POMC NPY HTR2A CRH
22 social phobia 31.2 SLC6A4 PRL HTR2A CRH CCK BDNF
23 autism spectrum disorder 31.2 SLC6A4 PYY POMC NPY LEP IGF1
24 osteoporosis 31.2 RETN PRL LEPR LEP IGF1 GHRL
25 generalized anxiety disorder 31.1 SLC6A4 NPY HTR2A BDNF
26 bipolar disorder 31.1 SLC6A4 PRL LEP IGF1 HTR2A CRH
27 type 1 diabetes mellitus 31.0 RETN LEPR LEP IGF1 GH1 ADIPOQ
28 alcohol dependence 31.0 SLC6A4 POMC NPY LEP HTR2A GHRL
29 endogenous depression 31.0 SLC6A4 PRL POMC HTR2A CRH BDNF
30 hyperthyroidism 31.0 RETN PRL POMC LEP IGF1 GHRL
31 schizoaffective disorder 31.0 SLC6A4 PRL HTR2A BDNF
32 psychotic disorder 31.0 SLC6A4 PRL HTR2A CCK BDNF ADIPOQ
33 ileus 31.0 POMC GHRL CRH CCK
34 conversion disorder 30.9 HTR2A CRH BDNF
35 somatoform disorder 30.9 SLC6A4 CRH BDNF
36 acute stress disorder 30.9 SLC6A4 POMC CRH BDNF
37 paranoid schizophrenia 30.9 SLC6A4 PRL HTR2A BDNF
38 dysthymic disorder 30.9 SLC6A4 POMC HTR2A CRH BDNF
39 non-alcoholic fatty liver disease 30.9 RETN LEPR LEP IGF1 ADIPOQ
40 anovulation 30.9 PRL LEP IGF1 GHRL CRH
41 turner syndrome 30.9 LEP IGF1 GHR GH1
42 post-traumatic stress disorder 30.9 SLC6A4 POMC HTR2A CRH BDNF ADIPOQ
43 nutritional deficiency disease 30.9 RETN NPY LEPR LEP IGF1 GHRL
44 asperger syndrome 30.8 SLC6A4 IGF1 BDNF
45 pituitary tumors 30.8 PRL POMC IGF1 GH1
46 hypothyroidism 30.8 RETN PRL POMC LEP IGF1 GHRH
47 gastroesophageal reflux 30.7 PYY NPY HTR2A GHRL CCK ADIPOQ
48 attention deficit-hyperactivity disorder 30.7 SLC6A4 PRL NPY HTR2A BDNF ADIPOQ
49 marasmus 30.7 IGF1 GH1
50 vascular disease 30.7 SLC6A4 RETN LEP IGF1 HTR2A ADIPOQ

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa

Symptoms & Phenotypes for Anorexia Nervosa

Clinical features from OMIM®:

606788 (Updated 20-May-2021)

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 ADIPOQ AGRP BDNF CCK CRH GHR
2 homeostasis/metabolism MP:0005376 10.36 ADIPOQ AGRP BDNF CCK CRH GHR
3 adipose tissue MP:0005375 10.32 ADIPOQ AGRP CRH GHR GHRH GHRL
4 endocrine/exocrine gland MP:0005379 10.32 ADIPOQ BDNF CCK CRH GHR GHRH
5 growth/size/body region MP:0005378 10.27 ADIPOQ AGRP BDNF CRH GHR GHRH
6 immune system MP:0005387 10.14 ADIPOQ CCK CRH GHR GHRH IGF1
7 nervous system MP:0003631 10.13 ADIPOQ AGRP BDNF CCK CRH GHR
8 integument MP:0010771 10.07 ADIPOQ BDNF CRH GHR IGF1 LEP
9 liver/biliary system MP:0005370 10.06 ADIPOQ AGRP CRH GHR GHRH LEP
10 normal MP:0002873 9.81 AGRP BDNF CRH GHRL IGF1 LEPR
11 renal/urinary system MP:0005367 9.61 ADIPOQ CCK CRH GHR IGF1 LEP
12 skeleton MP:0005390 9.32 ADIPOQ CRH GHR GHRH HTR2A IGF1

Drugs & Therapeutics for Anorexia Nervosa

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Cycloserine Approved Phase 4 68-41-7 401 6234
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
9 Psychotropic Drugs Phase 4
10 Analgesics Phase 4
11 Dopamine agonists Phase 4
12 Serotonin Uptake Inhibitors Phase 4
13 Antidepressive Agents Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Antiemetics Phase 4
16 Gastrointestinal Agents Phase 4
17 Antipsychotic Agents Phase 4
18 Dopamine Agents Phase 4
19 Dopamine Antagonists Phase 4
20 Quetiapine Fumarate Phase 4 111974-72-2
21 Anti-Infective Agents Phase 4
22 Serotonin 5-HT1 Receptor Agonists Phase 4
23 Serotonin Receptor Agonists Phase 4
24 Antimetabolites Phase 4
25 Antibiotics, Antitubercular Phase 4
26 Anti-Bacterial Agents Phase 4
27 Antitubercular Agents Phase 4
28 Retinol palmitate Phase 4
29 retinol Phase 4
30 Anesthetics, Dissociative Phase 4
31 Anesthetics, General Phase 4
32 Anesthetics Phase 4
33 Anesthetics, Intravenous Phase 4
34 Excitatory Amino Acid Antagonists Phase 4
35
Benztropine Phase 4 86-13-5 6832
36
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
37
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850
38
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
39
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
40
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
41
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
42
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
43
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
44
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
45
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
46
Risedronate Approved, Investigational Phase 2, Phase 3 105462-24-6 5245
47
Etidronic acid Approved Phase 2, Phase 3 2809-21-4, 7414-83-7 3305
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Mecasermin Approved, Investigational Phase 3 68562-41-4

Interventional clinical trials:

(show top 50) (show all 267)
# Name Status NCT ID Phase Drugs
1 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
2 Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
3 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
4 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
5 NMDA Antagonists in Bipolar Depression Completed NCT01833897 Phase 4 Standard of Care;Ketamine;D-cycloserine
6 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
7 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
8 Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial Unknown status NCT01082848 Phase 3 aripiprazole;placebo
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
11 Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
12 Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
13 Effects of Anorexia Nervosa on Peak Bone Mass Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
14 IGF-1 and Bone Loss in Women Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
15 The Role of Lactobacillus Reuteri in Nutritional Recovery and Treatment of Constipation in Children and Adolescents With Anorexia Nervosa - Randomised, Double Blind, Placebo Controlled Study Completed NCT02004288 Phase 2, Phase 3
16 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
17 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
18 Effects of Anorexia Nervosa on Peak Bone Mass Active, not recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
19 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Terminated NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
20 Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial Terminated NCT01184443 Phase 3 Olanzapine
21 A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa Unknown status NCT01761942 Phase 2
22 The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
23 Addressing Fear of Food in Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
24 Therapeutic Effects of Alpha-neurofeedback in the Treatment of Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
25 The Role of PTH in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
26 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
27 A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
28 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Completed NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
29 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
30 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
31 Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study Completed NCT00260962 Phase 2 Olanzapine
32 Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
33 Atypical Antipsychotic Medication in Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
34 Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
35 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
36 Treatment for Adolescent Anorexia Nervosa Completed NCT00183586 Phase 2
37 CRAFT: Helping Parents Initiate and Support Their Adolescent's Treatment Completed NCT01344382 Phase 1, Phase 2
38 The Safety, Tolerability, and Initial Efficacy of Psilocybin in Participants With Anorexia Nervosa Recruiting NCT04661514 Phase 2 Psilocybin
39 Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa Recruiting NCT03875378 Phase 2 Transdermal estrogen;Placebos
40 Efficacy of Adapted Program of Physiotherapy in Hospitalized Person by Anorexia Nervosa With Several Undernutrition Active, not recruiting NCT04190290 Phase 2
41 An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders Not yet recruiting NCT04454684 Phase 2 MDMA
42 Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study Not yet recruiting NCT04505189 Phase 1, Phase 2 Psilocybin
43 Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effects of an Estrogen-progestin Combination as add-on to Inpatient Psychotherapy in Adult Female Patients Suffering From Anorexia Nervosa Terminated NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
44 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
45 The Effect of Testosterone Replacement on Bone Mineral Density and Bone Microarchitecture in Teenage Boys and Young Adult Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
46 A Clinical Trial Into the Efficacy of rTMS Treatment for Treating Anorexia Nervosa and Bulimia Nervosa Withdrawn NCT04061304 Phase 2
47 Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
48 Cognitive Remediation Therapy for Anorexia Nervosa Completed NCT00601822 Phase 1
49 Acceptance Based Separated Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
50 Repetitive Transcranial Magnetic Stimulation of the Dorsomedial Prefrontal Cortex as a Treatment for Anorexia Nervosa and Bulimia Nervosa: An Open-Label Case Series Completed NCT04409704 Phase 1

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Genetic Tests for Anorexia Nervosa

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa 1 29 HTR2A

Anatomical Context for Anorexia Nervosa

MalaCards organs/tissues related to Anorexia Nervosa:

40
Bone, Brain, Pituitary, Liver, Heart, Bone Marrow, Cortex

Publications for Anorexia Nervosa

Articles related to Anorexia Nervosa:

(show top 50) (show all 13504)
# Title Authors PMID Year
1
Haplotype analysis of the COMT-ARVCF gene region in Israeli anorexia nervosa family trios. 57 61 54
16118784 2005
2
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 57 54 61
15523490 2005
3
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. 57 54 61
14681918 2004
4
Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. 61 54 57
11317231 2001
5
Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. 61 57
18855537 2008
6
Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. 61 57
16152574 2005
7
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. 57 61
11799475 2002
8
Linkage analysis of anorexia nervosa incorporating behavioral covariates. 57 61
11912184 2002
9
Anorexia nervosa and major depression: shared genetic and environmental risk factors. 61 57
10698830 2000
10
A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. 57 61
9672050 1998
11
Mortality in anorexia nervosa. 61 57
7793446 1995
12
Anorexia nervosa: a study of 34 twin pairs and one set of triplets. 61 57
6593110 1984
13
Significant linkage on chromosome 10p in families with bulimia nervosa. 57
12476400 2003
14
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 54 61
20339027 2010
15
Peptide YY levels across pubertal stages and associations with growth hormone. 54 61
20375207 2010
16
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 54 61
20195875 2010
17
Possible involvement of ghrelin on pain threshold in obesity. 54 61
19883981 2010
18
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. 54 61
19931436 2010
19
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 61 54
18574484 2010
20
Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. 54 61
19926712 2010
21
Adipocyte fatty acid binding protein during refeeding of female patients with anorexia nervosa. 61 54
19421706 2009
22
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 61 54
19741568 2009
23
[Neuropeptide Y, ghrelin and leptin plasma levels in anorexia nervosa patients and their changes during six-week refeeding]. 54 61
19947235 2009
24
Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. 54 61
19659925 2009
25
Leptin deficiency: clinical implications and opportunities for therapeutic interventions. 54 61
19730134 2009
26
Leptin concentration indexed to fat mass is increased in untreated anorexia nervosa (AN) patients. 61 54
18803679 2009
27
Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. 54 61
19568484 2009
28
Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. 54 61
18752728 2009
29
[Relationships of hormones of adipose tissue and ghrelin to bone metabolism]. 54 61
19662887 2009
30
The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa. 54 61
19296912 2009
31
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 54 61
19046818 2009
32
Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. 54 61
18926548 2009
33
Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. 54 61
18995969 2009
34
Leptin in humans: lessons from translational research. 54 61
19176740 2009
35
NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. 54 61
20066808 2009
36
Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. 61 54
19176730 2009
37
Leptin and its associations with measures of psychopathology in patients with anorexia nervosa. 54 61
19018447 2009
38
Hypercaloric diets differing in fat composition have similar effects on serum leptin and weight gain in female subjects with anorexia nervosa. 54 61
19185771 2009
39
Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. 61 54
19755753 2009
40
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. 61 54
19093738 2009
41
Serum concentrations of adipocyte fatty acid binding protein in patients with anorexia nervosa. 54 61
18657008 2009
42
The role of ghrelin in the regulation of food intake in patients with obesity and anorexia nervosa. 54 61
18380540 2009
43
Mecasermin (recombinant human insulin-like growth factor I). 61 54
19198769 2009
44
Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study. 61 54
18639866 2008
45
Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. 61 54
18474361 2008
46
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 54 61
18728162 2008
47
Surged leptin/ghrelin secretion associated with anorexia nervosa. 54 61
18955869 2008
48
Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. 54 61
19014633 2008
49
The endocrinopathies of anorexia nervosa. 61 54
19095609 2008
50
Growth hormone, insulin-like growth factors, and the skeleton. 61 54
18436706 2008

Variations for Anorexia Nervosa

Expression for Anorexia Nervosa

Search GEO for disease gene expression data for Anorexia Nervosa.

Pathways for Anorexia Nervosa

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 PYY PRL POMC NPY LEPR LEP
2
Show member pathways
12.48 POMC GHRH GH1 CRH BDNF
3
Show member pathways
12.33 LEPR LEP IGF1 ADIPOQ
4
Show member pathways
12.31 PRL LEPR LEP GH1
5
Show member pathways
12.2 PRL LEPR LEP GHR GH1
6 12.17 POMC NPY GHRL BDNF
8
Show member pathways
12.03 POMC LEP IGF1 GHRL GH1
9 11.84 RETN LEP IGF1 GH1 ADIPOQ
10 11.7 LEP IGF1 ADIPOQ
11 11.51 IGF1 GHR GH1
12 11.35 PRL LEPR LEP
13 11.27 POMC NPY LEPR LEP AGRP ADIPOQ
14
Show member pathways
11.25 PRL GHR GH1
15
Show member pathways
11.09 POMC LEPR LEP
16 10.53 PYY PRL POMC NPY LEPR LEP
17 10.36 POMC CRH

GO Terms for Anorexia Nervosa

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 RETN PYY PRL POMC NPY LEPR
2 neuronal cell body GO:0043025 9.65 HTR2A GHR CRH CCK AGRP
3 extracellular space GO:0005615 9.53 RETN PYY PRL POMC NPY LEP
4 growth hormone receptor complex GO:0070195 9.16 GHR GH1

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.19 PYY POMC NPY HTR2A GHRL GHRH
2 signal transduction GO:0007165 10.11 RETN PRL POMC LEP IGF1 HTR2A
3 response to drug GO:0042493 10.01 SLC6A4 HTR2A CRH ADIPOQ
4 positive regulation of protein phosphorylation GO:0001934 9.97 LEPR LEP CRH ADIPOQ
5 positive regulation of cell proliferation GO:0008284 9.95 PRL LEP IGF1 HTR2A GHRH CRH
6 glucose homeostasis GO:0042593 9.9 POMC LEPR LEP ADIPOQ
7 cellular response to insulin stimulus GO:0032869 9.89 LEP GHR ADIPOQ
8 response to estradiol GO:0032355 9.89 SLC6A4 LEP GHR GH1
9 female pregnancy GO:0007565 9.88 PRL LEP CRH
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 LEP IGF1 GH1
11 neuropeptide signaling pathway GO:0007218 9.88 PYY POMC NPY AGRP
12 response to nutrient GO:0007584 9.87 SLC6A4 LEP ADIPOQ
13 response to insulin GO:0032868 9.86 RETN LEP AGRP
14 regulation of blood pressure GO:0008217 9.85 POMC NPY LEP
15 glucose metabolic process GO:0006006 9.84 LEP GHRL ADIPOQ
16 positive regulation of cold-induced thermogenesis GO:0120162 9.84 LEPR LEP GHRL ADIPOQ
17 circadian rhythm GO:0007623 9.83 SLC6A4 LEP AGRP ADIPOQ
18 hormone-mediated signaling pathway GO:0009755 9.81 GHRL GHR AGRP
19 memory GO:0007613 9.81 SLC6A4 HTR2A CCK BDNF
20 negative regulation of tumor necrosis factor production GO:0032720 9.8 POMC IGF1 GHRL ADIPOQ
21 feeding behavior GO:0007631 9.78 PYY NPY AGRP
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 LEP IGF1 GHR GH1
23 regulation of multicellular organism growth GO:0040014 9.73 PRL IGF1 GHR
24 eating behavior GO:0042755 9.72 LEP CCK AGRP
25 energy reserve metabolic process GO:0006112 9.71 LEPR LEP
26 insulin-like growth factor receptor signaling pathway GO:0048009 9.71 IGF1 GHR
27 growth hormone receptor signaling pathway GO:0060396 9.7 GHR GH1
28 positive regulation of growth GO:0045927 9.7 GHRL GH1
29 hormone metabolic process GO:0042445 9.7 LEP GHR
30 regulation of feeding behavior GO:0060259 9.69 LEPR AGRP
31 leptin-mediated signaling pathway GO:0033210 9.68 LEPR LEP
32 negative regulation of appetite GO:0032099 9.68 LEP CCK
33 sexual reproduction GO:0019953 9.68 LEPR LEP
34 intestinal epithelial cell differentiation GO:0060575 9.68 PYY NPY
35 positive regulation of growth hormone secretion GO:0060124 9.67 GHRL GHRH
36 positive regulation of behavioral fear response GO:2000987 9.66 CRH CCK
37 positive regulation of feeding behavior GO:2000253 9.65 GHRL AGRP
38 bone mineralization involved in bone maturation GO:0035630 9.65 LEP IGF1
39 bone growth GO:0098868 9.65 LEPR LEP
40 regulation of bone remodeling GO:0046850 9.64 LEPR LEP
41 growth hormone secretion GO:0030252 9.64 GHRL GHRH
42 positive regulation of corticotropin secretion GO:0051461 9.63 GHRL CRH
43 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.63 PRL GHR GH1
44 negative regulation of glucagon secretion GO:0070093 9.62 LEP CRH
45 positive regulation of cortisol secretion GO:0051464 9.62 GHRL CRH
46 positive regulation of JAK-STAT cascade GO:0046427 9.62 PRL LEP GHR GH1
47 positive regulation of appetite GO:0032100 9.61 NPY GHRL
48 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.61 IGF1 GHRH GH1
49 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.57 GHRL CRH
50 positive regulation of multicellular organism growth GO:0040018 9.56 GHRL GHRH GHR GH1

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.7 POMC NPY LEP CRH BDNF AGRP
2 G protein-coupled receptor binding GO:0001664 9.62 PYY POMC NPY GHRL
3 serotonin binding GO:0051378 9.48 SLC6A4 HTR2A
4 type 1 melanocortin receptor binding GO:0070996 9.46 POMC AGRP
5 hormone activity GO:0005179 9.44 RETN PYY PRL POMC NPY LEP
6 neuropeptide Y receptor binding GO:0031841 9.43 PYY NPY
7 peptide hormone receptor binding GO:0051428 9.43 LEP GHRH CCK
8 neuropeptide hormone activity GO:0005184 9.43 PYY NPY GHRH CRH CCK AGRP
9 growth hormone-releasing hormone activity GO:0016608 9.4 GHRL GHRH
10 prolactin receptor binding GO:0005148 9.37 PRL GH1

Sources for Anorexia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....